{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["SearchResults"],"not_rendered":{"images":1,"comments":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"SearchResults","index":0,"n_rows":31,"n_cols":11,"rows_kept":31,"merged":[[0,1,0,8]],"flags":["formulas_cached_only"]}
[null,"Overzicht PSMA clinical trials"]
[null,"Start Date","Completion Date","Acronym","Title","Status","Conditions","Interventions","Locations","URL","PI/contact person"]
[1,2020,2021,"PSMA-GBM","18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme","Unknown status","Glioblastoma Multiforme","Other: 18F-PSMA-1007 PET tracer","Radboudumc","https://ClinicalTrials.gov/show/NCT04588454","Radboudumc"]
[2,2022,2024,null,"PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas","Recruiting","Sarcoma,Soft Tissue|Urothelial Carcinoma","Diagnostic Test: [18F]-JK-PSMA-7 PET/CT scan","LUMC","https://ClinicalTrials.gov/show/NCT05522257","Lioe-Fee De Geus-Oei"]
[3,2021,2023,"PROQURE-1","EBRT + Lu-PSMA for N1M0 Prostate Cancer","Recruiting","Prostatic Neoplasm","Drug: 177Lu-PSMA-617|Radiation: EBRT","NKI-AvL","https://ClinicalTrials.gov/show/NCT05162573","Wouter Vogel"]
[4,2022,2024,"MIMETIC","Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer","Recruiting","Medullary Thyroid Cancer|Medullary Thyroid Carcinoma|Thyroid Carcinoma, Medullary|Thyroid Cancer, Medullary","Drug: 18F-PSMA-1007","UMCG","https://ClinicalTrials.gov/show/NCT05534594","Adrienne Brouwers"]
[5,2023,2026,"PET-MaN-enza","PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide","Not yet recruiting","Prostate Cancer","Diagnostic Test: PSMA-PET/CT response evaluation","UMCU/Antonius Ziekenhuis, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT05539300","Roderick van den Bergh"]
[6,2020,2025,"LUPSA","Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients","Recruiting","Salivary Gland Cancer|Salivary Duct Carcinoma|Adenoid Cystic Carcinoma","Drug: Lutetium-177-PSMA-I&T","Radboudumc","https://ClinicalTrials.gov/show/NCT04291300","Carla ML van Herpen"]
[7,2020,2023,"ADT-SCAN","PSMA-PET Imaging Before and After ADT in Advanced SDC Patients","Recruiting","Salivary Gland Cancer|Salivary Duct Carcinoma","Diagnostic Test: 68Ga-PSMA-PET/CT|Diagnostic Test: 18FDG-PET/CT","Radboudumc","https://ClinicalTrials.gov/show/NCT04214353","Carla ML van Herpen"]
[8,2017,2018,null,"PSMA-PET Imaging for Advanced ACC/SDC","Completed","Salivary Gland Cancer|Adenoid Cystic Carcinoma|Salivary Duct Carcinoma","Diagnostic Test: PSMA-PET/CT scan","Radboudumc","https://ClinicalTrials.gov/show/NCT03319641","Carla ML van Herpen"]
[9,2020,2023,"PROPER-ABX","F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer","Unknown status","Prostate Cancer Recurrent","Diagnostic Test: F18-fluciclovine PET/CT|Diagnostic Test: F18-PSMA-1007 PET/CT","Radboudumc","https://ClinicalTrials.gov/show/NCT04239742","James Nagarajah"]
[10,2020,2022,"PICture","18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer","Recruiting","Prostate Cancer","Diagnostic Test: 18F-PSMA-1007 PET/CT","Radboudumc","https://ClinicalTrials.gov/show/NCT04487847","James Nagarajah"]
[11,2018,2019,null,"Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer","Completed","Prostate Neoplasm","Drug: Lu-177 PSMA-617","Radboudumc","https://ClinicalTrials.gov/show/NCT03828838","James Nagarajah"]
[12,2021,2026,"PSMA-SELECT","Dutch National Randomized Study: PSMA-PET/CT as a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients","Recruiting","Prostate Cancer Metastatic|Prostate Cancer|Lymph Node Metastases","Device: PSMA-PET/CT|Other: Nomogram","Canisius Wilhelmina Ziekenhuis, Nijmegen","https://ClinicalTrials.gov/show/NCT05000827","Jean-Paul van Basten"]
[13,null,2020,"MAGNIFY","Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI","Unknown status","Prostate Cancer|Lymph Node Metastases","Diagnostic Test: Ferumoxtran-10 enhanced MRI","Radboudumc | Catharina Ziekenhuis Eindhoven |Canisius Wilhelmina Ziekenhuis\nNijmegen","https://clinicaltrials.gov/ct2/show/NCT03223064","Fred Witjes"]
[14,2021,2025,"PET-MaN","PSMA Response in Metastasized Hormone Sensitive Prostate Cancer","Recruiting","Prostate Cancer","Diagnostic Test: PSMA-PET/CT","Meander MC|Canisius-Wilhelmina Ziekenhuis, Nijmegen|St Antonius Utrecht|UMCU","https://ClinicalTrials.gov/show/NCT05161728","Roderick van den Bergh"]
[15,2020,2024,"Bullseye","Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer","Recruiting","Prostate Cancer","Drug: 177Lu-PSMA-617","AmsterdamUMC|NKI-AvL|UMCG|Radboudumc","https://ClinicalTrials.gov/show/NCT04443062","James Nagarajah"]
[16,2017,2021,null,"Dose-Effect Relation of Salivary Gland Irradiation","Completed","HNSCC","Device: PSMA PET/CT-scan","NKI-AVL|UMCG|UMCU","https://ClinicalTrials.gov/show/NCT03367780","Wouter Vogel"]
[17,2020,2022,"TRACE","Technetium Based Radioguided Surgery for Prostate Cancer (TRACE) Study","Unknown status","Prostate Cancer","Procedure: PSMA-radioguided surgery","NKI-AvL","https://ClinicalTrials.gov/show/NCT03857113","Pim van Leeuwen"]
[18,2021,2028,"SPLASH","Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment","Recruiting","Metastatic Castration-Resistant Prostate Cancer","Drug: [Lu-177]-PNT2002|Drug: Abiraterone|Drug: Enzalutamide","St. Antonius Nieuwegein|Radboudumc|Erasmus UMC|groot internationaal","https://ClinicalTrials.gov/show/NCT04647526","POINT biopharma"]
[19,2021,2023,"POTENTIA","Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.","Recruiting","Advanced and/or Metastatic Solid Tumours","Drug: CB307","NKI-AvL|Amsterdam UMC|UMCG|Erasmus UMC|UMCU|groot internationaal","https://ClinicalTrials.gov/show/NCT04839991","Crescendo Biologics Ltd."]
[20,2020,2030,"PERYTON","PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy","Recruiting","Prostate Cancer|Cancer Recurrence","Radiation: Conventional sEBRT|Radiation: Hypofractionated sEBRT","Radiotherapy Institute Friesland|Radiotherapiegroep, Arnhem|Radboudumc|Maastro Clinic, Maastricht|Catharina-Hospital, Eindhoven|Verbeeten Institute, Tilburg|Amsterdam UMC|Deventer|Haga Hospital, Den Haag, |LUMC|Erasmus MC|UMCG","https://ClinicalTrials.gov/show/NCT04642027","Shafak Al-Uwini"]
[21,2021,2026,"PSMAddition","An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC","Recruiting","Prostatic Neoplasms","Drug: 177Lu-PSMA-617|Drug: 68Ga-PSMA-11|Drug: ARDT|Drug: ADT","Novartis","https://ClinicalTrials.gov/show/NCT04720157","AAA/Novartis"]
[22,2018,2023,"VISION","Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer","Active, not recruiting","Prostate Cancer","Drug: 177Lu-PSMA-617|Other: Best supportive/best standard of care","NKI-AvL|St. Antonius Nieuwegein|Radboudumc|UMCU| groot internationaal","https://ClinicalTrials.gov/show/NCT03511664","AAA/Novartis"]
[23,2021,2025,"PSMAfore","177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","Active, not recruiting","Prostatic Neoplasms","Drug: 177Lu-PSMA-617|Drug: 68Ga-PSMA-11|Drug: ARDT|Other: Best supportive care","Novartis","https://ClinicalTrials.gov/show/NCT04689828","AAA/Novartis"]
[24,2020,2023,"DETECT","Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer Patients","Active, not recruiting","Prostate Cancer|Lymph Node Metastases","Procedure: Radio guided surgery (RGS) using Indium-labelled PSMA","Radboudumc|Canisius Wilhelimina Ziekenhuis, Nijmegen","https://ClinicalTrials.gov/show/NCT04300673","Michiel Sedelaar"]
[25,2021,2022,null,"Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer","Recruiting","Prostate Cancer|Prostate Cancer Recurrent","Drug: [18F]PSMA-1007","RadboudUMC | internationaal","https://ClinicalTrials.gov/show/NCT04742361","ABX advanced biochemical compounds"]
[26,2019,2025,null,"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","Active, not recruiting","Metastatic Castration-resistant Prostate Cancer|Prostate Cancer","Drug: acapatamab|Drug: Pembrolizumab|Drug: Etanercept|Drug: Cytochrome P450 (CYP) Cocktail","Erasmus MC|groot internationaal","https://ClinicalTrials.gov/show/NCT03792841","Amgen"]
[27,2020,2021,"SPOTLIGHT","Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)","Completed","Prostate Cancer","Drug: rhPSMA-7.3 (18F) Injection","CWZ, Nijmegen |Maxima MC, Veldhoven | groot internationaal","https://ClinicalTrials.gov/show/NCT04186845","Blue Earth Diagnostics"]
[28,2020,2022,"LIGHTHOUSE","Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)","Completed","Prostate Cancer","Drug: rhPSMA-7.3 (18F) Injection","CWZ, Nijmegen|Maxima MC, Veldhoven | groot internationaal","https://ClinicalTrials.gov/show/NCT04186819","Blue Earth Diagnostics"]
[29,2020,2022,"ADOPT","Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy","Recruiting","Prostate Cancer","Radiation: Radiotherapy|Drug: Leuprorelin","Friesland|Arnhem|Radboudumc|Maastricht|Catharina Hospital, Eindhoven|Amsterdam UMC | Deventer| Zwolle|Haga Hospital, Den Haag|LUMC|Erasmus MC|UMCG|Verbeeten Institute, Tilburg","https://ClinicalTrials.gov/show/NCT04302454","Shafak Al-Uwini"]